Tenax Therapeutics, Inc.

NasdaqCM:TENX Stock Report

Market Cap: US$15.3m

Tenax Therapeutics Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Chris Giordano

Chief executive officer

US$644.8k

Total compensation

CEO salary percentage62.9%
CEO tenure3.3yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20
Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

CEO Compensation Analysis

How has Chris Giordano's remuneration changed compared to Tenax Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$645kUS$405k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$667kUS$386k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$861kUS$183k

-US$32m

Compensation vs Market: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD655.65K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Giordano (50 yo)

3.3yrs

Tenure

US$644,770

Compensation

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kno data
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Lawrence Hoffman
Interim Chief Financial Officerless than a yearno datano data
Doug Randall
Executive Vice President of Commercial & Business Operationsno datano datano data
Douglas Hay
Senior Vice President of Regulatory Affairsno datano datano data

3.3yrs

Average Tenure

69yo

Average Age

Experienced Management: TENX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77kno data
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Gerald Proehl
Independent Chairman10.6yrsUS$88.50k0.049%
$ 7.5k
Michael Davidson
Independent Director3.8yrsUS$57.50k0.085%
$ 12.9k
Daniel Burkhoff
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsno datano data
Declan Doogan
Independent Director3.8yrsUS$48.50k0.067%
$ 10.2k
Robyn Hunter
Independent Director2.8yrsUS$65.00k0%
$ 0
June Almenoff
Independent Director3.8yrsUS$59.50k0%
$ 0
Sanjiv Shah
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrsno datano data
Barry Borlaug
Member of PH-Left Heart Disease Scientific Advisory Board4.8yrsno datano data
Robert Frantz
Member of PAH Scientific Advisory Boardno datano datano data
Anna Hemnes
Member of PAH Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

67yo

Average Age

Experienced Board: TENX's board of directors are considered experienced (3.8 years average tenure).